Reducing recurrence and costs in superficial bladder cancer: Preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin

International Journal of Clinical Practice

Volumn 60, Issue 10, 2006, Pages 1178-1180

  Fechner, Guido ^a   Pocha, K ^a   Schmidt, D ^a   Muller S C ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Bladder cancer; Instillation; Mitomycin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MITOMYCIN; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG CYTOTOXICITY; DRUG EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOLAYER CULTURE; OSMOSIS; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; SUPERFICIAL CANCER; TUMOR CELL DESTRUCTION; TUMOR VOLUME;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; CELL SURVIVAL; COST SAVINGS; HUMANS; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; OSMOLAR CONCENTRATION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; WATER;

EID: 33748538651     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00847.x     Document Type: Article

References (11)

1. Jemal A, Tiwari RC, Murray T et al.; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 2004; 171 (6 Pt 1): 2186-90, quiz 2435.
3. Kaasinen E, Rintala E, Hellstrom P et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002; 42: 167-74.
4. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am 1992; 19: 529-39.
5. Levin DR, Moskovitz B. Distilled water versus chemotherapeutic agents for transitional bladder carcinoma. Eur Urol 1986; 12: 418-21.
6. Mack D, Rammal E, Jakse G. Iatrogenic tumor cell implantation in bladder cancer. Urologe A 1988; 27: 99-104.
7. Pode D, Horowitz AT, Vlodavsky I, Shapiro A, Biran S. Prevention of human bladder tumor cell implantation in an in vitro assay. J Urol 1987; 137: 777-81.
8. Bolkier M, Moskovitz B, Ginesin Y, Levin DR. Effect of distilled water and bacillus Calmette-Guerin on exfoliated bladder tumor cells. Eur Urol 1991; 19: 319-21.
9. Singh SV, Scalamogna D, Xia H et al. Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line. Int J Cancer 1996; 65: 852-7.
10. Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L. The use of valrubicin for the chemoresection of superficial bladder cancer - a marker lesion study. Eur Urol 2001; 39: 643-7.
11. Calais da Silva F, Denis L, Bono A, Bollack C, Bouffioux C. Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors. Eur Urol 1988; 14: 207-9.